Jubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore and net debt at Rs. 2,457 crore. In FY24, the company reported revenue of Rs. 6,772 crore and a net profit of Rs. 195 crore. The net debt to Ebitda ratio improved from 2.93x to 2.48x.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.